US Irritable Bowel Syndrome Treatment Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. US Irritable Bowel Syndrome Treatment Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. US Irritable Bowel Syndrome Treatment Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. US Irritable Bowel Syndrome Treatment Market Regional Analysis

6.2 US Irritable Bowel Syndrome Treatment Market Revenue 2017-2027 (US$ Million)

6.3 US Irritable Bowel Syndrome Treatment Market Forecast Analysis

7. US Irritable Bowel Syndrome Treatment Market Analysis – by Type

7.1 IBS with Diarrhea

7.1.1 Overview
7.1.2 IBS with Diarrhea: US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.2 IBS with Constipation

7.2.1 Overview
7.2.2 IBS with Constipation: US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

7.3 Mixed IBS

7.3.1 Overview
7.3.2 Mixed IBS: US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

8. US Irritable Bowel Syndrome Treatment Market Analysis – by Product

8.1 Rifaximin

8.1.1 Overview
8.1.2 Rifaximin: US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.2 Eluxadoline

8.2.1 Overview
8.2.2 Eluxadoline: US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.3 Lubiprostone

8.3.1 Overview
8.3.2 Lubiprostone: US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

8.4 Linaclotide

8.4.1 Overview
8.4.2 Linaclotide: US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

9. US Irritable Bowel Syndrome Treatment Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview
9.1.2 Hospital Pharmacies: US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.2 Drug Stores and Retail Pharmacies

9.2.1 Overview
9.2.2 Drug Stores and Retail Pharmacies: US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

9.3 Online Pharmacies

9.3.1 Overview
9.3.2 Online Pharmacies : US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)

10. US Irritable Bowel Syndrome Treatment Market – United States Analysis

10.1 Overview

10.2 United States

10.2.1 US Irritable Bowel Syndrome Treatment Market Breakdown, by Key Country, 2020 and 2027 (%)
10.2.1.1 US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast Analysis – by Country
10.2.1.1 United States : US Irritable Bowel Syndrome Treatment Market – Revenue and Forecast to 2027 (US$ Million)

10.2.1.1.1 United States : US Irritable Bowel Syndrome Treatment Market Breakdown, by Type
10.2.1.1.2 United States : US Irritable Bowel Syndrome Treatment Market Breakdown, by Product
10.2.1.1.3 United States : US Irritable Bowel Syndrome Treatment Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Ironwood Pharmaceuticals, Inc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Allergan Plc.

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Sebela Pharmaceuticals, Inc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Takeda Pharmaceutical Company Limited

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Alfasigma S.p.A.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Astellas Pharma Inc.

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 AstraZeneca

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Synthetic Biologics, Inc.

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Bausch + Lomb Incorporated

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Lannett Company Inc.

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

US Irritable Bowel Syndrome Treatment Market